These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27150364)

  • 1. Heterocyclic Naphthalimides as New Skeleton Structure of Compounds with Increasingly Expanding Relational Medicinal Applications.
    Gong HH; Addla D; Lv JS; Zhou CH
    Curr Top Med Chem; 2016; 16(28):3303-3364. PubMed ID: 27150364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naphthalimide derivatives with therapeutic characteristics: a patent review.
    Kamal A; Bolla NR; Srikanth PS; Srivastava AK
    Expert Opin Ther Pat; 2013 Mar; 23(3):299-317. PubMed ID: 23369185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naphthalimides and azonafides as promising anti-cancer agents.
    Ingrassia L; Lefranc F; Kiss R; Mijatovic T
    Curr Med Chem; 2009; 16(10):1192-213. PubMed ID: 19355879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current developments of coumarin compounds in medicinal chemistry.
    Peng XM; Damu GL; Zhou C
    Curr Pharm Des; 2013; 19(21):3884-930. PubMed ID: 23438968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the development of 1,8-naphthalimide based DNA targeting binders, anticancer and fluorescent cellular imaging agents.
    Banerjee S; Veale EB; Phelan CM; Murphy SA; Tocci GM; Gillespie LJ; Frimannsson DO; Kelly JM; Gunnlaugsson T
    Chem Soc Rev; 2013 Feb; 42(4):1601-18. PubMed ID: 23325367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxo-heterocyclic fused naphthalimides as antitumor agents: synthesis and biological evaluation.
    Tan S; Yin H; Chen Z; Qian X; Xu Y
    Eur J Med Chem; 2013 Apr; 62():130-8. PubMed ID: 23353750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colorimetric and fluorescent anion sensors: an overview of recent developments in the use of 1,8-naphthalimide-based chemosensors.
    Duke RM; Veale EB; Pfeffer FM; Kruger PE; Gunnlaugsson T
    Chem Soc Rev; 2010 Oct; 39(10):3936-53. PubMed ID: 20818454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research Progress on Structure-Activity Relationship of 1,8-Naphthalimide DNA Chimeras Against Tumor.
    Zhang HY; Han LL; Wu HY; Xu XX; Yu MB; Chen GY; Qi XL
    Technol Cancer Res Treat; 2024; 23():15330338231225861. PubMed ID: 38225189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gold(I) N-heterocyclic carbene complexes with naphthalimide ligands as combined thioredoxin reductase inhibitors and DNA intercalators.
    Meyer A; Oehninger L; Geldmacher Y; Alborzinia H; Wölfl S; Sheldrick WS; Ott I
    ChemMedChem; 2014 Aug; 9(8):1794-800. PubMed ID: 24803348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of naphthalimide analogs as anticancer agents.
    Lv M; Xu H
    Curr Med Chem; 2009; 16(36):4797-813. PubMed ID: 19929786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxygen- and Sulphur-Containing Heterocyclic Compounds as Potential Anticancer Agents.
    Sachdeva H; Khaturia S; Saquib M; Khatik N; Khandelwal AR; Meena R; Sharma K
    Appl Biochem Biotechnol; 2022 Dec; 194(12):6438-6467. PubMed ID: 35900713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent developments on 1,8-Naphthalimide moiety as potential target for anticancer agents.
    Tandon R; Luxami V; Tandon N; Paul K
    Bioorg Chem; 2022 Apr; 121():105677. PubMed ID: 35202852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Medicinal Chemist's Perspective Towards Structure Activity Relationship of Heterocycle Based Anticancer Agents.
    Nehra B; Mathew B; Chawla PA
    Curr Top Med Chem; 2022; 22(6):493-528. PubMed ID: 35021975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Outlook of the Structure Activity Relationship (SAR) of Naphthalimide Derivatives as Anticancer Agents.
    Bhat AA
    Anticancer Agents Med Chem; 2024; 24(2):96-116. PubMed ID: 37974443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel metal complexes of naphthalimide-cyclam conjugates as potential multi-target receptor tyrosine kinase (RTK) inhibitors: synthesis and biological evaluation.
    Tan S; Han K; Li Q; Tong L; Yang Y; Chen Z; Xie H; Ding J; Qian X; Xu Y
    Eur J Med Chem; 2014 Oct; 85():207-14. PubMed ID: 25084146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advance in oxazole-based medicinal chemistry.
    Zhang HZ; Zhao ZL; Zhou CH
    Eur J Med Chem; 2018 Jan; 144():444-492. PubMed ID: 29288945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naphthalimide-based triptycenes: synthesis and optoelectronic properties.
    Wu D; Zhang H; Liu SH; Yin J
    Chem Asian J; 2015 Mar; 10(3):602-7. PubMed ID: 25556653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly sensitive and selective Pd2+ sensor of naphthalimide derivative based on complexation with alkynes and thio-heterocycle.
    Duan L; Xu Y; Qian X
    Chem Commun (Camb); 2008 Dec; (47):6339-41. PubMed ID: 19048148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Ruthenium(II) N-Heterocyclic Carbene (NHC) Complex with Naphthalimide Ligand Triggers Apoptosis in Colorectal Cancer Cells via Activating the ROS-p38 MAPK Pathway.
    Dabiri Y; Schmid A; Theobald J; Blagojevic B; Streciwilk W; Ott I; Wölfl S; Cheng X
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,8-Naphthalimide: A Potent DNA Intercalator and Target for Cancer Therapy.
    Tandon R; Luxami V; Kaur H; Tandon N; Paul K
    Chem Rec; 2017 Oct; 17(10):956-993. PubMed ID: 28375569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.